文献速递食管胃疾病与幽门螺杆菌消化道肿瘤与早癌

通过13C-尿素呼气试验筛查根除幽门螺杆菌以预防原住民社区胃癌:一项基于人群的研究及家庭指示病例方法的建立

Eradicating Helicobacter pylori via 13C-urea breath screening to prevent gastric cancer in indigenous communities: a population-based study and development of a family index-case method.
PubMed 文献 · Gut · 2023-11-24

该研究在台湾原住民社区纳入20-60岁居民,采用13C-尿素呼气试验进行检测-治疗-复检-复治方案,评估幽门螺杆菌筛查根除的可接受性与可行性,并建立家庭指示病例方法。共纳入15057名参与者,参与率80.0%,阳性率44.1%,根除率91.7%(意向性分析)和92.1%(符合方案分析),因不良反应停药率1.2%,结论为高参与率、高根除率和有效推广方法表明该一级预防策略在原住民社区可接受且可行。

要点

  • 参与率80.0%,幽门螺杆菌阳性率44.1%。
  • 阳性指示病例的家庭成员感染率是阴性指示病例家庭成员的1.98倍(95%CI 1.03-3.80)。
  • 根除率91.7%(意向性分析)和92.1%(符合方案分析),因不良反应停药率1.2%。

核心结论

  • 高参与率、高幽门螺杆菌根除率和有效的推广方法表明,一级预防策略在原住民社区可接受且可行。

研究设计与样本

  • 研究纳入台湾原住民社区20-60岁居民,接受13C-尿素呼气试验及四联抗生素治疗的检测-治疗-复检-复治方案。
  • 研究邀请参与者的家庭成员(构成指示病例)加入项目,并评估阳性指示病例的家庭成员感染率是否更高。
  • 2018年9月24日至2021年12月31日期间,共纳入15057名参与者(8852名原住民和6205名非原住民),参与率80.0%(15057/18821名受邀者)。

主要发现

  • 幽门螺杆菌阳性率为44.1%(95%CI 43.3%-44.9%)。
  • 在72个原住民家庭(258名参与者)的概念验证研究中,阳性指示病例的家庭成员幽门螺杆菌感染率是阴性指示病例家庭成员的1.98倍(95%CI 1.03-3.80)。
  • 在大规模筛查环境中纳入1115个原住民家庭和555个非原住民家庭(4157名参与者),重复验证结果为1.95倍(95%CI 1.61-2.36)。
  • 6643名检测阳性者中,5493名(82.6%)接受了治疗。
  • 根据意向性分析和符合方案分析,一至两个疗程治疗后根除率分别为91.7%(95%CI 89.1%-94.3%)和92.1%(95%CI 89.2%-95.0%)。

局限性

  • 原文未报告局限性。

以上解读依据论文摘要(全文未开放获取或许可不允许翻译转载)。

原文

OBJECTIVE: Screening and eradication of Helicobacter pylori help reduce disparities in the incidence of gastric cancer. We aimed to evaluate its acceptability and feasibility in the indigenous communities and develop a family index-case method to roll out this programme. DESIGN: We enrolled residents aged 20-60 years from Taiwanese indigenous communities to receive a course of test, treat, retest and re-treat initial treatment failures with the 13C-urea breath tests and four-drug antibiotic treatments. We also invited the family members of a participant (constituting an index case) to join the programme and evaluated whether the infection rate would be higher in the positive index cases. RESULTS: Between 24 September 2018 and 31 December 2021, 15 057 participants (8852 indigenous and 6205 non-indigenous) were enrolled, with a participation rate of 80.0% (15 057 of 18 821 invitees). The positivity rate was 44.1% (95% CI 43.3% to 44.9%). In the proof-of-concept study with 72 indigenous families (258 participants), family members of a positive index case had 1.98 times (95% CI 1.03 to 3.80) higher prevalence of H. pylori than those of a negative index case. The results were replicated in the mass screening setting (1.95 times, 95% CI 1.61 to 2.36) when 1115 indigenous and 555 non-indigenous families were included (4157 participants). Of the 6643 testing positive, 5493 (82.6%) received treatment. According to intention-to-treat and per-protocol analyses, the eradication rates were 91.7% (89.1% to 94.3%) and 92.1% (89.2% to 95.0%), respectively, after one to two courses of treatment. The rate of adverse effects leading to treatment discontinuation was low at 1.2% (0.9% to 1.5%). CONCLUSION: A high participation rate, a high eradication rate of H. pylori and an efficient rollout method indicate that a primary prevention strategy is acceptable and feasible in indigenous communities. TRIAL REGISTRATION NUMBER: NCT03900910.

来源:Gut,查看原文。版权归原作者所有。

引用

  1. Lei WY, Lee JY, Chuang SL, et al. Eradicating Helicobacter pylori via 13C-urea breath screening to prevent gastric cancer in indigenous communities: a population-based study and development of a family index-case method. Gut. 2023. PMID: 37197905. doi:10.1136/gutjnl-2023-329871

供执业医师工作参考,不替代临床判断;数值与分级以指南原文为准。